• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BioAtla Inc.

    8/7/24 4:26:16 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    SC 13G 1 BCAB_SC13G.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    BIOATLA, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.0001 PER SHARE
    (Title of Class of Securities)

    09077B104
    (CUSIP Number)

    AUGUST 5, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    09077B104

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,414,815
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,414,815
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,414,815
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    09077B104

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,414,815
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,414,815
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,414,815
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    09077B104

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,414,815
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,414,815
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,414,815
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.0%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    09077B104

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      BioAtla, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    11085 Torreyana Road
    San Diego, California 92121

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.0001 per share ("Common Stock")
     
      (e) CUSIP Number:
    09077B104
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    09077B104

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    09077B104

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    09077B104

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of August 6, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    09077B104

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: August 6, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    09077B104

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of BioAtla, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: August 6, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $BCAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioAtla downgraded by H.C. Wainwright

      H.C. Wainwright downgraded BioAtla from Buy to Neutral

      11/13/24 7:31:56 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on BioAtla with a new price target

      JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

      9/15/22 7:31:28 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla downgraded by Credit Suisse with a new price target

      Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously

      5/5/22 6:12:47 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Vasquez Christian was granted 85,000 shares, increasing direct ownership by 44% to 276,696 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:55 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Short Jay M Phd was granted 431,000 shares, increasing direct ownership by 24% to 2,256,372 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Waldron Richard A was granted 100,000 shares, increasing direct ownership by 43% to 333,263 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    See more
    • BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

      SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

      12/21/21 9:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

      SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

      11/14/24 4:00:05 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      10/2/24 4:30:04 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      9/6/24 4:59:38 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      1/19/24 4:21:50 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/26/23 7:43:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/20/23 6:27:44 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by BioAtla Inc.

      SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)

      5/20/25 2:26:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 5:05:56 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by BioAtla Inc.

      424B3 - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 4:22:32 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Participate in the Citizens Life Sciences Conference

      SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one investor meetingsDate: Wednesday, May 7, 2025Time: 10:00 a.m. ETLocation: New York, NYWebcast Link: Click Here About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operation

      4/30/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Financials

    Live finance-specific insights

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu

      3/27/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care